Thalidomide and hematopoietic-cell transplantation for multiple myeloma

The New England Journal of Medicine
Bart BarlogieJohn Crowley

Abstract

High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival. Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. A total of 323 were randomly assigned to receive thalidomide from the outset until disease progression or undue adverse effects, and 345 did not receive thalidomide. The primary end point was the five-year event-free survival rate. Secondary end points were complete response and overall survival. After a median follow-up of 42 months among survivors, the thalidomide and control groups had rates of complete response of 62 percent and 43 percent, respectively (P<0.001), and five-year event-free survival rates of 56 percent and 44 percent (P=0.01). The five-year rate of overall survival was approximately 65 percent in both groups (P=0.90). Median survival after relapse was 1.1 years in the thalidomide group and 2.7 years in the control group (P=0.001). Severe peripheral neuropathy a...Continue Reading

References

Aug 1, 1985·The Journal of Clinical Investigation·B BarlogieL Smith
Apr 1, 1989·Annals of Internal Medicine·B BarlogieR Alexanian
May 24, 1984·The New England Journal of Medicine·B BarlogieR Alexanian
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarThomas E Witzig
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Choon-Kee LeeGuido Tricot
Sep 13, 2003·Blood·Bart BarlogieJohn Crowley
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Aug 5, 2005·Nature Medicine·Charles L Sawyers

❮ Previous
Next ❯

Citations

Oct 15, 2008·Intensive Care Medicine·Vincent PeigneElie Azoulay
Jan 6, 2007·Annals of Hematology·Francesco A PiazzaGianpietro Semenzato
Nov 1, 2007·Clinical and Experimental Medicine·F MerchionneF Dammacco
Apr 17, 2008·Cancer Metastasis Reviews·Aaron P BrownKevin A Camphausen
Oct 16, 2008·Journal of Behavioral Medicine·Allen C ShermanElias J Anaissie
Jul 17, 2013·Frontiers of Medicine·Miao XuJun Peng
Aug 24, 2007·Current Treatment Options in Oncology·Seema Singhal, Jayesh Mehta
Oct 26, 2013·Current Hematologic Malignancy Reports·Jordan Schecter, Suzanne Lentzsch
Feb 20, 2010·Medical Oncology·Jacob P LaubachKenneth C Anderson
Mar 12, 2013·International Journal of Hematology·Reiko WatanabeMasahiro Kizaki
Oct 12, 2010·The Lancet Oncology·Michel DelforgePieter Sonneveld
Sep 25, 2008·Bone Marrow Transplantation·J Mehta, S Singhal
Nov 14, 2008·Leukemia·A Palumbo, S V Rajkumar
Aug 10, 2012·Leukemia·F MagrangeasS Minvielle
Nov 3, 2006·Nature Clinical Practice. Oncology·Paul G RichardsonKenneth C Anderson
Mar 20, 2008·Nature Clinical Practice. Oncology·Paolo Corradini, Vittorio Montefusco
Sep 30, 2009·Nature Reviews. Clinical Oncology·Jacob P LaubachKenneth C Anderson
Sep 5, 2007·Bone Marrow Transplantation·M S RaabK C Anderson
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Mar 9, 2007·Leukemia·R MihelicS Lonial
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
Jun 2, 2006·The New England Journal of Medicine·Judah Folkman, Michael S Rogers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.